The genetics of drug efficacy: opportunities and challenges

被引:0
|
作者
Matthew R. Nelson
Toby Johnson
Liling Warren
Arlene R. Hughes
Stephanie L. Chissoe
Chun-Fang Xu
Dawn M. Waterworth
机构
[1] Target Sciences,
[2] GlaxoSmithKline,undefined
[3] King of Prussia,undefined
[4] Target Sciences,undefined
[5] GlaxoSmithKline,undefined
[6] GlaxoSmithKline,undefined
[7] PAREXEL International,undefined
[8] Target Sciences,undefined
[9] GlaxoSmithKline,undefined
[10] Present address: Acclarogen,undefined
[11] Cambridge CB4 0WS,undefined
[12] UK.,undefined
来源
Nature Reviews Genetics | 2016年 / 17卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
To date, there have been at least 76 genome-wide association studies and a large number of candidate gene studies of drug efficacy. From these, there are at least 12 drugs with high-confidence genetic predictors of drug efficacy.Genetic predictors of drug efficacy are mostly common variants with a range of effect sizes; most have been discovered through studies of sensitive quantitative measures of drug response, and all but one were discovered following drug approval.Less than 20% of drugs are estimated to have common genetic predictors of efficacy that are large enough to inform clinical decision making.There are limited scenarios in which genetics can 'rescue' a trial that fails owing to lack of efficacy. However, advances in genetic technologies can allow for cost-effective screening for genetic predictors with potential clinical utility during the course of clinical development.Pharmaceutical and academic researchers should combine resources to study the efficacy pharmacogenetics of marketed drugs.
引用
收藏
页码:197 / 206
页数:9
相关论文
共 50 条
  • [21] Opportunities and challenges for artificial intelligence in clinical cardiovascular genetics
    Krittanawong, Chayakrit
    Johnson, Kipp W.
    Glicksberg, Benjamin S.
    TRENDS IN GENETICS, 2021, 37 (09) : 780 - 783
  • [22] A view on clinical genetics and genomics in Spain: of challenges and opportunities
    Pampols, Teresa
    Ramos, Feliciano J.
    Lapunzina, Pablo
    Gozalo-Salellas, Ignasi
    Perez-Jurado, Luis A.
    Pujol, Aurora
    MOLECULAR GENETICS & GENOMIC MEDICINE, 2016, 4 (04): : 376 - 391
  • [23] Minding the gap in HIV host genetics: opportunities and challenges
    Shanelle N. Gingras
    David Tang
    Jeffrey Tuff
    Paul J. McLaren
    Human Genetics, 2020, 139 : 865 - 875
  • [24] Challenges and opportunities in NASH drug development
    Harrison, Stephen A.
    Allen, Alina M.
    Dubourg, Julie
    Noureddin, Mazen
    Alkhouri, Naim
    NATURE MEDICINE, 2023, 29 (03) : 562 - 573
  • [25] Drug discovery in China: challenges and opportunities
    Ling Wang
    NationalScienceReview, 2018, 5 (05) : 768 - 773
  • [26] Anthelmintics for drug repurposing: Opportunities and challenges
    Alavi, Seyed Ebrahim
    Shahmabadi, Hasan Ebrahimi
    SAUDI PHARMACEUTICAL JOURNAL, 2021, 29 (05) : 434 - 445
  • [27] Opportunities and challenges in antiparasitic drug discovery
    Pink, R
    Hudson, A
    Mouriès, MA
    Bendig, M
    NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (09) : 727 - 740
  • [28] Opportunities and Challenges in Antiparasitic Drug Discovery
    Richard Pink
    Alan Hudson
    Marie-Annick Mouriès
    Mary Bendig
    Nature Reviews Drug Discovery, 2005, 4 : 727 - 740
  • [29] Drug delivery to the retina: challenges and opportunities
    Duvvuri, S
    Majumdar, S
    Mitra, AK
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2003, 3 (01) : 45 - 56
  • [30] Pediatric Drug Development: Challenges and Opportunities
    Spadoni, Cesare
    CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, 2019, 90 : 119 - 122